---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-024024"
form_type: "8-K/A"
ticker: "XOMA"
cik: "0000791908"
company_name: "XOMA Royalty Corp"
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:39:53.570056+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# XOMA files Pulmokine financials for $20M cash acquisition closed Nov 26, 2024

## Summary
- XOMA acquired Pulmokine for $20M cash at closing; historical audited and unaudited financials filed.
- Pulmokine 2023 revenue $10M (milestone) and net income $7.95M; cash $708K at year-end.
- Pro forma condensed combined balance sheet and income statements filed as Exhibit 99.4.
- Pulmokine is a biopharma developing inhaled PDGFR inhibitor for pulmonary arterial hypertension.
- Exhibits include audited FY2023, unaudited 9M2024 financials, and independent auditor consent.

## SEC filing metadata
- accession: 0001193125-25-024024
- form_type: 8-K/A
- ticker: XOMA
- cik: 0000791908
- company_name: XOMA Royalty Corp
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/791908/000119312525024024/0001193125-25-024024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/791908/000119312525024024/d935049d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-024024
- JSON: https://secwatch.observer/filing/0001193125-25-024024.json
- Plain text: https://secwatch.observer/filing/0001193125-25-024024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.